Literature DB >> 19536390

A review of the cost of cardiovascular disease.

Jean-Eric Tarride1, Morgan Lim, Marie DesMeules, Wei Luo, Natasha Burke, Daria O'Reilly, James Bowen, Ron Goeree.   

Abstract

In Canada, 74,255 deaths (33% of all deaths) in 2003 were due to cardio-vascular disease (CVD). As one of the most costly diseases, CVD represents a major economic burden on health care systems. The purpose of the present study was to review the literature on the economic costs of CVD in Canada and other developed countries (United States, Europe and Australia) published from 1998 to 2006, with a focus on Canada. Of 1656 screened titles and abstracts, 34 articles were reviewed including six Canadian studies and 17 American studies. While considerable variation was observed among studies, all studies indicated that the costs of treating CVD-related conditions are significant, outlining a convincing case for CVD prevention programs.

Entities:  

Mesh:

Year:  2009        PMID: 19536390      PMCID: PMC2722492          DOI: 10.1016/s0828-282x(09)70098-4

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  31 in total

Review 1.  Economic evidence in stroke: a review.

Authors:  Mattias Ekman
Journal:  Eur J Health Econ       Date:  2004-10

2.  Cost of stroke in Europe.

Authors:  T Truelsen; M Ekman; G Boysen
Journal:  Eur J Neurol       Date:  2005-06       Impact factor: 6.089

3.  Epidemiology of recurrent cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost.

Authors:  G P Samsa; J Bian; J Lipscomb; D B Matchar
Journal:  Stroke       Date:  1999-02       Impact factor: 7.914

4.  Medical resource use and costs of health care after acute stroke in Germany.

Authors:  K Rossnagel; C H Nolte; J Muller-Nordhorn; G J Jungehulsing; D Selim; B Bruggenjurgen; A Villringer; S N Willich
Journal:  Eur J Neurol       Date:  2005-11       Impact factor: 6.089

5.  Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO.

Authors:  S P Amin; C D Mullins; B S Duncan; L Blandford
Journal:  Am J Health Syst Pharm       Date:  1999-08-01       Impact factor: 2.637

6.  Cost of illness of chronic angina.

Authors:  Harold S Javitz; Marcia M Ward; Jennifer B Watson; Mirou Jaana
Journal:  Am J Manag Care       Date:  2004-10       Impact factor: 2.229

7.  Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.

Authors:  Alicia C Sasser; Matthew D Rousculp; Howard G Birnbaum; Emily F Oster; Edward Lufkin; David Mallet
Journal:  Womens Health Issues       Date:  2005 May-Jun

8.  Costs and medical care consequences associated with the diagnosis of peripheral arterial disease.

Authors:  Kristen Migliaccio-Walle; J Jaime Caro; Khajak J Ishak; Judith A O'Brien
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

9.  Total first-year costs of acute coronary syndrome in a managed care setting.

Authors:  Lida R Etemad; Patrick L McCollam
Journal:  J Manag Care Pharm       Date:  2005-05

10.  Long-term cost and life-expectancy consequences of hypertension.

Authors:  U Kiiskinen; E Vartiainen; P Puska; A Aromaa
Journal:  J Hypertens       Date:  1998-08       Impact factor: 4.844

View more
  67 in total

1.  Visfatin, glucose metabolism and vascular disease: a review of evidence.

Authors:  Pedro Saddi-Rosa; Carolina S V Oliveira; Fernando M A Giuffrida; André F Reis
Journal:  Diabetol Metab Syndr       Date:  2010-03-26       Impact factor: 3.320

Review 2.  Cardiac gene therapy: are we there yet?

Authors:  P N Matkar; H Leong-Poi; K K Singh
Journal:  Gene Ther       Date:  2016-04-29       Impact factor: 5.250

Review 3.  Ageing, metabolism and cardiovascular disease.

Authors:  Sarah Costantino; Francesco Paneni; Francesco Cosentino
Journal:  J Physiol       Date:  2015-10-22       Impact factor: 5.182

4.  Cell death signalling mechanisms in heart failure.

Authors:  Wajihah Mughal; Lorrie A Kirshenbaum
Journal:  Exp Clin Cardiol       Date:  2011

5.  Costs of hospitalization for stroke patients aged 18-64 years in the United States.

Authors:  Guijing Wang; Zefeng Zhang; Carma Ayala; Diane O Dunet; Jing Fang; Mary G George
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-08-15       Impact factor: 2.136

6.  Direct cost for initial management of prostate cancer: a systematic review.

Authors:  C Sanyal; A G Aprikian; S Chevalier; F L Cury; A Dragomir
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

7.  Inhibitors of soluble epoxide hydrolase minimize ischemia-reperfusion-induced cardiac damage in normal, hypertensive, and diabetic rats.

Authors:  Oliul Islam; Prashanth Patil; Sumanta K Goswami; Rema Razdan; Mohammed N Inamdar; Mohammed Rizwan; Jubin Mathew; Bora Inceoglu; Kin S Stephen Lee; Sung H Hwang; Bruce D Hammock
Journal:  Cardiovasc Ther       Date:  2017-06       Impact factor: 3.023

8.  Deciphering STAT3 signaling in the heart: plasticity and vascular inflammation.

Authors:  Mazen Kurdi; George W Booz
Journal:  Congest Heart Fail       Date:  2010 Sep-Oct

9.  Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis.

Authors:  Lucía Ramos; Jorge Novo; Noelia Barreira; José Rouco; Manuel G Penedo; Marcos Ortega
Journal:  J Vis Exp       Date:  2018-09-26       Impact factor: 1.355

10.  Oral hygiene and cardiometabolic disease risk in the survey of the health of Wisconsin.

Authors:  Jeffrey J VanWormer; Amit Acharya; Robert T Greenlee; Francisco Javier Nieto
Journal:  Community Dent Oral Epidemiol       Date:  2012-10-29       Impact factor: 3.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.